Thrasos: Thrasos Announces Promising Results for Phase 2 THR184 Dose Ranging Clinical Study for the Prevention of Acute Kidney Injury AKI

Thrasos Therapeutics a biotherapeutics company focused on delivering new solutions for kidney disease today announced it has successfully completed its Phase 2 firstinpatients dose ranging clinical study of THR184 for the prevention...